F-star Therapeutics (F-star Therapeutics) ROCE % : -93.43% (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is F-star Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. F-star Therapeutics's annualized ROCE % for the quarter that ended in Sep. 2022 was -93.43%.

F-star Therapeutics ROCE % Historical Data

The historical data trend for F-star Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

F-star Therapeutics ROCE % Chart

F-star Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

ROCE %

-213.61

-89.17

-39.12

F-star Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
ROCE %	Get a 7-Day Free Trial							-37.89	16.61	-44.25	-79.67	-93.43

F-star Therapeutics ROCE % Calculation

F-star Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	-30.811	/	( ( (63.609 - 16.977)	+	(123.021 - 12.135) )	/ 2 )
	=	-30.811	/	( (46.632	+	110.886)	/ 2 )
	=	-30.811	/	78.759
	=	-39.12 %

F-star Therapeutics's ROCE % of for the quarter that ended in Sep. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	-72.116	/	( ( (100.644 - 15.317)	+	(83.717 - 14.675) )	/ 2 )
	=	-72.116	/	( ( 85.327	+	69.042 )	/ 2 )
	=	-72.116	/	77.1845
	=	-93.43 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

F-star Therapeutics (NAS:FSTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

F-star Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of F-star Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

F-star Therapeutics (F-star Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » F-star Therapeutics Inc (NAS:FSTX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Babraham Research Campus, Eddeva B920, Cambridge, GBR, CB22 3AT

Website

https://www.f-star.com

F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.

Executives

Geoffrey Race	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Edward Jr Benz	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Darlene M Deptula-hicks	officer: See Remarks	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Eliot Forster	director, officer: PRESIDENT AND CEO	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Nessan Bermingham	director	890 WINTER STREET, WALTHAM MA 02451
Louis Kayitalire	officer: CHIEF MEDICAL OFFICER	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Neil Brewis	officer: CHIEF SCIENTIFIC OFFICER	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pamela M. Klein	director	35 PARKWOOD DRIVE, SUITE 210, HOPKINTON MA 01748
Krol Patrick Johan Hendrik	director	GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Garrett Winslow	officer: General Counsel and Secretary	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Lori Firmani	officer: VP of Finance and Treasurer	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTCALS, INC., HOPKINTON MA 01748
Scott Andrew Smith	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Timothy P Clackson	director	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christiana Bardon	director, 10 percent owner	86 SOUTH STREET, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Mpm Oncology Impact Management Lp	10 percent owner	399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116